Connecting you to content on EBSCOhost

Works matching IS 11732563 AND DT 2025 AND VI 45 AND IP 2

Results: 5

1

Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity: Phase I RCT of S-309309 in Obesity: T. Ishibashi et al.

Published in:

Clinical Drug Investigation, 2025, v. 45, n. 2, p. 85, doi. 10.1007/s40261-024-01418-3

By:

Ishibashi, Toru;
Tanioka, Hideki;
Ikehara, Tatsuya;
Kezbor, Safwan;
Sonoyama, Takuhiro

Publication type:

Article

2

Assessment of Reperfusion Efficacy of Altelyse Versus Actilyse in Patients with Acute Myocardial Infarction: A Phase 3, Randomized, Double-Blinded, Non-inferiority Clinical Trial: Altelyse Versus Actilyse: M. R. Beyranvand et al.

Published in:

Clinical Drug Investigation, 2025, v. 45, n. 2, p. 101, doi. 10.1007/s40261-025-01420-3

By:

Beyranvand, Mohammad Reza;
Asadpour Piranfar, Mohammad;
Solaymani-Dodaran, Masoud;
Mohebbi, Nahid;
Taati, Reyhaneh;
Sheibani, Mehdi;
Shahami, Mohammadreza;
Masoumi, Safdar;
Shahraz, Saeid;
Manhoobi, Hootan

Publication type:

Article

3

Comparison of Pharmacokinetics of Long-Acting Local Analgesics: CPL-01, a Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Exposure Compared with Liposomal Bupivacaine: Novel Extended-Release Ropivacaine Shows Consistent and Predictable PK: S. Pope et al

Published in:

Clinical Drug Investigation, 2025, v. 45, n. 2, p. 51, doi. 10.1007/s40261-025-01419-w

By:

Pope, Stevie;
Crean, Christopher;
Thrasher, Sarah;
Xu, Hanghang;
Chen, P. J.;
Chen, Lee;
Hu, DeeDee;
Onel, Erol

Publication type:

Article

4

Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints: Real World Safety of Using Icosapent Ethyl in Nationwide VHA Cohort: T. Patil et al

Published in:

Clinical Drug Investigation, 2025, v. 45, n. 2, p. 69, doi. 10.1007/s40261-024-01417-4

By:

Patil, Tanvi;
Gregory, Michael;
Savona, Natalie;
Jarmukli, Nabil;
Leonard, Charles E.

Publication type:

Article

5

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2− Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered: Non-medication Expenses of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A. Pilehvari et al

Published in:

Clinical Drug Investigation, 2025, v. 45, n. 2, p. 59, doi. 10.1007/s40261-024-01416-5

By:

Pilehvari, Asal;
You, Wen;
Kimmick, Gretchen;
Camacho, Fabian;
Bonilla, Gloribel;
Anderson, Roger

Publication type:

Article